...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Additional Exempt Distribution

By my count, Don and Company in 2023 raised over $23 Million (CAN) thus far for ZCC. 

 

Koo

Share
New Message
Please login to post a reply